Asthma and bronchiectasis: Another duo on the respiratory stage

Ruxandra Ulmeanu1,2, Ruxandra-Mioara Rajnoveanu3, Sabina-Antonela Antoniu4, Lavinia Davidescu1, Milena-Adina Man5, Ana-Florica Chis5, Nicoleta-Stefania Motoc5, Armand-Gabriel Rajnoveanu6

Abstract:
The overlap between asthma and bronchiectasis (BE) is a challenging topic not only for researchers but also for clinicians. The aim of this review was to explore the latest insight of literature focused on the association between asthma and BE from the epidemiological, clinical, functional, and therapeutical perspectives. The literature search included papers published in English in the PUBMED database in the past 10 years. From a total of 233 findings, after eliminating those nonrelated to the topic and after using additional sources, 32 relevant articles were considered. The main results of the present review highlighted that when the two conditions are associated, patients have poorer clinical outcomes, greater disease severity and exacerbation rates, increased hospitalization trend, and risk for pulmonary complications, compared with each disease alone. As future directions, the need to identify both conditions at an early stage and to offer personalized management of these different phenotypes are goals to be further addressed.

Keywords:
Asthma, bronchiectasis, overlap, personalized management, severe asthma

Introduction

Asthma and bronchiectasis (BE) are two common heterogeneous airway diseases worldwide that can coexist in some patients and therefore raise different clinical, therapeutic, and prognosis implications.[1,2] The association between BE and asthma is an ongoing research topic, which still needs evidence from diverse perspectives.[3] The coexistence of BE and asthma is not rare, but it is often unrecognized and challenging, not only in terms of diagnosis but also regarding
the impact on different outcomes including therapeutic management and success.[4,5] The fact that both conditions share similarities in terms of clinical manifestations (cough, sputum, wheezing, dyspnea, and obstructive pattern), clinical outcomes, or functional pattern creates even greater challenges in daily clinical practice.[6]

BE may complicate asthma at any age, not only in adults but also in children and adolescents; therefore, complex approaches and management are required.[7]

In our review, we explored the latest insight of literature focused on the overlap between asthma and BE from the epidemiological, clinical, functional, and therapeutical perspectives.

**Methodology**

This narrative review was based on the search from electronic data sources using the PubMed (MEDLINE) database. There was no need for ethics committee approval as this study was a synthesis of published studies.

The initial search strategy on the keywords bronchiectasis and asthma identified 233 results. When not applied, the Boolean operator AND did not change the total number of results. The publication date of the search was in the past 10 years between January 16, 2011, and October 16, 2021. The search included full-text systematic reviews, reviews, meta-analysis, clinical trials, and randomized controlled trials published in English. We supplemented our electronic database search with additional records relevant to the topic. After eliminating articles nonrelated to the topic, duplicates, and after using additional sources, 32 articles with relevance to the aim of the study were considered. Table 1 provides information about some of the articles considered.

**Asthma with comorbid bronchiectasis**

Despite recent data focused on the etiopathogenesis of BE, just about 50% of them have a clear cause.[8,9] The perspective that BE is a consequence of asthma and thus needs time to develop is described in numerous studies.[8-10]

In the light of updated evidence, asthma, and in particular long-term uncontrolled asthma, may be seen as a structural and functional airway disorder favoring the development of BE.[3,11] The clear cause and effect relationship between asthma and BE is still debatable[12] and has not yet been precisely established,[9] particularly due to the lack of relevant animal studies.[12] Despite these uncertainties, bronchial asthma is considered the sixth leading cause of BE with a range between 3% and 7%.[8] According to the British Thoracic Society recommendations, asthma needs to be considered as a cause of BE in the absence of other etiologies.[13-15]

With the increased use of the thoracic high-resolution computed tomography (HRCT), the presence of BE in asthmatics, particularly in the severe phenotypes,[16-18] is more frequently identified, with a range from 0.8% to 77% according to real-life data.[19-19,21] The role of the HRCT in the diagnosis of BE in different chronic obstructive lung diseases including asthma patients is of greatest value, as for many years, the data about the presence of the bronchial dilatation in asthmatics was mainly obtained from Dunnill’s autopsy findings in 1960,[22] though in the pediatric population with severe asthma, there is poor evidence of routine use of HRCT.[7,23] The destruction of the bronchi and the permanent airway remodeling by an inflammatory process or recurrent infection are possible explanations for the prevalence of bronchial dilation in asthma patients.[24]

Another possible link between the two diseases was related to the immunoglobulin (Ig) and IgG subclass deficiency.[25,26] Toward these data, a recent finding of Luján et al.[27] was that the prevalence of BE in asthma seems to be related to the steroid requirements. According to this case-control cross-sectional study, steroid-dependent asthma seems to be at higher risk for BE, compared with non-steroid-dependent asthma. A possible explanation is a disease itself, not other contributors like the Ig levels.[27]

BE should be considered as both a differential diagnosis for and a comorbidity in asthmatics, particularly in long-standing or severe asthma.[28] A common pitfall in clinical practice is that sometimes in asthmatics the clinical features of BE are less visible due to the symptoms of asthma.[3,10]

In the light of these results, the current international asthma and chronic obstructive pulmonary disease (COPD) guidelines[29,30] recommend investigating the possible coexistence of BE defined as “treatable trait.”
Table 1: Most relevant information documents

| Author | Year | Title | Article type |
|--------|------|-------|--------------|
| Chen FJ, Liao H, Huang XY, Xie CM | 2016 | Importance of fractional exhaled nitric oxide in diagnosis of bronchiectasis accompanied with bronchial asthma | Original article |
| Padilla-Gaio A, Olveira C, et al. | 2018 | Factors associated with bronchiectasis in patients with uncontrolled asthma; the NOPES score: A study in 398 patients | Original article |
| Zhang SQ et al. | 2021 | Clinical features of asthma with comorbid bronchiectasis: A systematic review and meta-analysis | Systematic review and meta-analysis |
| Crimi C, Ferri S, Campisi R, Crimi N | 2019 | The link between asthma and bronchiectasis: State of the art | Clinical investigation |
| Polverino E, Dimakou K, Hurst J, et al. | 2018 | The overlap between bronchiectasis and chronic airway diseases: State of the art and future directions | Review article |
| Polverino E, Goeminne PC, et al. | 2017 | European Respiratory Society guidelines for the management of adult bronchiectasis | Task force reports |
| Maglione M, Aksamit T, Santamaria F | 2019 | Paediatric and adult bronchiectasis: Specific management with coexisting asthma, COPD, rheumatological disease and inflammatory bowel disease | Review article |
| Lonni S et al. | 2015 | Etiology of non-cystic fibrosis bronchiectasis in adults and its correlation to disease severity | Original research |
| Ferri S et al. | 2020 | Impact of asthma on bronchiectasis severity and risk of exacerbations | Research article |
| Mäntylä J, Mazur W, Törölä T, et al. | 2019 | A morphologic study of the airway structure abnormalities in patients with asthma by high-resolution computed tomography | Original article |
| Wang D et al. | 2016 | Asthma as aetiology of bronchiectasis in Finland | Original article |
| Amati F, Franceschi E, Gramegna A, et al. | 2017 | Investigating the etiology of bronchiectasis: You do not find what you do not look for | Letter to editor |
| Dimakou K et al. | 2018 | Investigation of bronchiectasis in severe uncontrolled asthma | Original article |
| Coman I, Pola-Bibiáñ B, Barranco P, et al. | 2018 | Bronchiectasis in severe asthma: Clinical features and outcomes | Research article |
| Mao B, Yang JW, Lu HW, Xu JF | 2016 | Asthma and bronchiectasis exacerbation | Original article |
| Luján M, Gallardo X, et al. | 2013 | Prevalence of bronchiectasis in asthma according to oral steroid requirement: Influence of immunoglobulin levels | Clinical study |
| Truong T | 2013 | The overlap of bronchiectasis and immunodeficiency with asthma | Review article |
| Oguzulgen IK, Kervan F, Ozis T, Turktas H | 2007 | The impact of bronchiectasis in clinical presentation of asthma | Clinical report |
| Kang HR et al. | 2014 | The effects of bronchiectasis on asthma exacerbation | Original article |
| Huang YJ | 2015 | The respiratory microbiome and innate immunity in asthma | Review article |
| Huang YJ, Boushey HA | 2015 | The microbiome in asthma | Review article and feature article |
| Chang HS et al. | 2017 | Neutrophilic inflammation in asthma: Mechanisms and therapeutic considerations | Review article |
| Whitters D, Stockley R | 2012 | Immunity and bacterial colonization in bronchiectasis | Review article |
| Chalmers JD, Chotirmall SH | 2018 | Bronchiectasis: New therapies and new perspectives | Review article |
| Porsberg C, Menzies-Gow A | 2017 | Co-morbidities in severe asthma: Clinical impact and management | Review article |
| Garcia-Clemente M, | 2020 | Severe asthma and bronchiectasis | Original article |
| Enriquez-Rodriguez AI, et al. | 2019 | Severe uncontrolled asthma with bronchiectasis: A pilot study of an emerging phenotype that responds to mepolizumab | Original research |
| Carpano GE, Sciscìa G, Lacedonia D, Curradi G, Barbaro MP | 2016 | Aetiology of bronchiectasis in adults: A systematic literature review | Systematic review |
| Gao YH et al. | 2019 | Comparative risks of chronic inhaled corticosteroids and macrolides for bronchiectasis | Original article |
| Henkle E et al. | 2018 | Anti-IL5 and anti-IL5Ra therapy for clinically significant bronchiectasis with eosinophilic endotype: A case series | Review letter |
| Rademacher J, Konwert S, et al. | 2014 | Is there a role for macrolides in severe asthma? | Review article |
| Sears MR | 2014 | Trends in the prevalence of asthma | Commentary |
| GINA | 2021 | Global Strategy for Asthma Management and Prevention | Guidelines |

*ERS: European Respiratory Society, †GINA: Global Initiative for Asthma*
This is of greatest importance in severe asthma cases, in recurrent infectious exacerbators, or in those not responding to standard therapy despite the optimal management. The suspicion of BE is also raised by the chronic cough/sputum ratio, the history of pneumonia, the evidence of neutrophilia, or Aspergillus sensitization.[6]

The data about the impact of BE on asthma are scarce since most asthma clinical studies are excluding those with coexisting BE.[31] The recent systematic review with meta-analysis of Zhang and colleagues, including five observational studies with 839 patients, highlighted that those with asthma and comorbid BE are older than patients with asthma alone, with no significant difference regarding sex, smoking history, and duration of asthma.[3] Some of these findings were also observed in the study of Luján et al.[27] where patients with asthma-associated BE were older and with longer-term asthma history compared with non-asthma-associated BE.

In clinical terms, the presence of chronic expectoration and purulent sputum in asthmatic patients highlights the importance to take into consideration the possible coexistence of BE. They not only are independent risk factors for the presence of BE but also correlate with chronic potentially pathogenic microorganisms (PPMs) colonization and antibiotic use.[2] Unfortunately, only a few studies focused on the data of chronic PPMs;[3] therefore this direction needs to be further explored.

Furthermore, patients with asthma and BE overlap have a poorer control, with increased asthma severity and severe and difficult-to-control asthma forms, higher exacerbation rate (in the previous year), and pulmonary complications, compared with patients with asthma alone.[3,24,32]

As contributing factors for these findings, more severe airflow obstruction and airway remodeling, oxidative stress,[33] a well-known contributor to the pathogenesis of different chronic diseases,[34,35] and mucus hypersecretion with subsequent formation of mucous plugs are closely related to asthma exacerbation in asthmatics with coexistent BE.[3,36,37]

In addition, the role of persistent bacterial airway colonization with a neutrophil-predominated inflammation and an active neutrophil elastase and protease pattern is an important risk factor for asthma exacerbation in patients with asthma and BE.[3,38,39]

**Bronchiectasis with comorbid asthma**

The prevalence of asthma in patients with BE has a large variability ranging from 2.7% to 42% depending on patient selection and type or severity of asthma.[3,8,19-21,31] Smoking history is an underlying common condition in several diseases, including asthma and BE.[40,41]

Although the influence of asthma on BE remains ambiguous, some evidence suggests a new phenotype of BE in the case of patients with BE and asthma.[21] According to a study by Ferri et al.,[9] compared with patients with BE alone, those with BE and coexistent asthma seem to be younger and show a significant association with atopy, chronic rhinosinusitis, or fractional exhaled nitric oxide (FeNO) levels, well known asthma-related features.

The presence of asthma is associated with an increased risk of BE exacerbation in patients with noncystic fibrosis BE.[21] Mao and colleagues reported that BE patients with coexistent asthma were 2.6 times more likely to suffer BE exacerbation than those without asthma, independent of other variables.[21] Ferri et al.[9] recently confirmed this finding and reported an independent increase in the risk of BE exacerbation in asthmatics with coexistent BE despite higher Bhalla score and lower Bronchiectasis Severity Index (BSI) compared with patients without asthma. The Bhalla score is used to assess the radiological severity of BE, with a maximum score of 25, and is inversely correlated with the radiological severity.[42] The BSI is a multidimensional scoring system used to assess the clinical severity, with an excellent predictive index for exacerbations, hospital admissions, and mortality.[43]

The main factors that may play a role in BE exacerbations are mucus hypersecretion, oxidative stress, airway remodeling, and microorganisms isolated from the lower respiratory airway of asthma patients.[36,37] Pseudomonas aeruginosa isolation from sputum samples is the major recognized independent risk factor for disease severity and exacerbation.[9]

**Bronchiectasis and difficult-to-control severe asthma**

Severe asthma may encounter in approximately 10% of asthma patients, and around 5% of these patients present difficult-to-control severe asthma.[24] Besides the overall
increased health-related costs, morbidity and mortality are higher, with 20 times greater risk for presentation in the emergency room and hospitalization compared with the less severe forms.[24]

The overlap between BE and severe asthma has consistent research evidence.[28] Moreover, the association between severe asthma and BE may be seen as an emerging phenotype.[44]

The prevalence of BE is more increased in severe asthma, with a range between 24% and 47%, compared with 3% in mild asthma.[17,24,45,46] It looks like almost a third of patients with uncontrolled moderate-to-severe asthma present concomitant BE.[2]

Though both diseases were classically related to the presence of allergic bronchopulmonary aspergillosis (ABPA), in the last years, the data showed an increased prevalence (30%) of BE in severe asthma even in the absence of ABPA.[2,46] The most prevalent BE is cylindrical (more than 90%) and bilateral, predominantly in the lower lobes.[2] Patients sharing both conditions are presenting a higher rate of pulmonary complications and hospitalization with respiratory failure.[20]

According to the systematic literature review of Gao and colleagues, in patients with severe asthma, BE increases the hospitalization rate with an odds ratio OR=2.09 compared with asthma without BE.[47]

In terms of prognosis, even the data for patients with asthma and BE are still narrow; those with severe asthma and BE overlap seem to be worse (clinical and exacerbation rate) compared with asthmatics without BE.[6,16,48]

**Allergy biomarkers in asthma-bronchiectasis overlap**

Regarding the blood eosinophil levels, they were significantly higher in patients with comorbid asthma and BE versus asthma alone (p=0.03).[3] The same finding was also observed when patients with BE and asthma were compared with those with BE alone.[9]

The impact on serum IgE levels was not found when compared patients with comorbid asthma and BE with patients without BE.[3]

**Functional features of asthma-bronchiectasis overlap**

Airway obstruction, in terms of postbronchodilator FEV₁/FVC ratio, is significantly more reduced in patients with comorbid asthma and BE when compared with patients with asthma alone according to the recent meta-analysis of Zhang and colleagues.[3] Lower FEV₁ and FEV₁/FVC values were also noticed in patients with asthma-associated BE compared with non-asthma-associated BE.[27]

Furthermore, the results of Mao et al.[21] showed that patients with BE and coexisting asthma have poorer small airway function than those with BE without asthma.

The FeNO measurement, with a cut-off point of 22.5 ppb (parts per billion) may be a good biomarker to distinguish asthma in BE patients, from those with BE but no asthma as suggested by Chen et al.[1] These results were consistent with those of Padilla-Galo et al.[2] In their prospective study on 398 patients, the optimal FeNO cut-off of 20.5 ppb was used to differentiate asthmatics with BE from patients without BE.[2]

Moreover, Padilla-Galo et al.[2] proposed the NOPES score, an easy-to-use scoring system with a high prognostic value for BE in uncontrolled moderate-to-severe asthma patients. The variables used for this score are FeNO, pneumonia, expectoration, and asthma severity. A high score (range 0–4) is related to a higher probability of BE in patients with uncontrolled moderate-to-severe asthma.

Still, further large-scale prospective studies are required for validation of the FeNO, the NOPES score, or other useful tools.[1,6,49–51]

**Concerns and perspectives regarding the treatment of the duo asthma-bronchiectasis**

In patients with asthma, inhaled corticosteroids (ICS) are the cornerstone of pharmacological management.[29,52] On the other hand, the latest European Respiratory Society guidelines[40] do not recommend the use of ICS in patients with BE, mainly because they seem to be involved in promoting a bacterial load, with consequent impact on exacerbations.[6,9,53] Still, if asthmatics are already on ICS treatment, the coexistence of BE alone is
A higher blood eosinophil count in patients with BE and concomitant asthma compared with BE or asthma alone is suggestive for a type 2 endotype inflammation and raises relevant implications on the treatment perspectives.\(^6\) Although limited clinical cases are currently reported in the literature, the target for new biological anti-interleukin 5 (IL-5) drugs in patients with BE and asthma is poorer, and long-term antibiotics and thoracic physiotherapy, as used in the management of BE, are frequently needed.\(^6\)

Long-term therapy with macrolides may be considered when asthma, particularly the severe phenotype, coexists with BE. Antibiotics can reduce the bacteria overload, bronchial inflammation, and exacerbation rate both in patients with BE and asthma.\(^3\) The treatment is effective and well tolerated.\(^4,5,5\)

### Final considerations

The increased interest in the scientific community for patients with asthma-BE overlap is multidimensional, targeting important knowledge gaps on pathophysiology, inflammatory features, risk factors, clinical phenotype, or prognosis. The need to timely and accurately recognize the presence of both conditions, to define specific therapeutic tools for each condition, and to choose the optimal management approach and follow-up interventions in patients with asthma-BE overlap remain goals for both research and clinical practice.

### Conflicts of interest

There are no conflicts of interest.

### Financial support and sponsorship

Nil.

### Peer-review

Externally peer-reviewed.

### Authorship Contributions

Concept – U.R.; R.R.M.; A.S.A.; D.L.; M.M.A.; C.A.F.; M.N.S.; R.A.G.; Design – U.R.; R.R.M.; A.S.A.; D.L.; M.M.A.; C.A.F.; M.N.S.; R.A.G.; Supervision – U.R.; R.R.M.; A.S.A.; D.L.; M.M.A.; C.A.F.; M.N.S.; R.A.G.; Funding – U.R.; R.R.M.; A.S.A., R.A.G.; Materials – U.R.; R.R.M.; A.S.A., R.A.G.; Data collection &/or processing – R.R.M., R.A.G.; Analysis and/or interpretation – U.R.; R.R.M.; A.S.A.; Literature search – R.R.M., D.L., M.M.A., C.A.F., M.N.S., R.A.G.; Writing – R.R.M., R.A.G.; Critical review – U.R., R.R.M., A.S.A., R.A.G.

### References

1. Chen FJ, Liao H, Huang XY, Xie CM. Importance of fractional exhaled nitric oxide in diagnosis of bronchiectasis accompanied with bronchial asthma. J Thorac Dis 2016;8:992–9. [CrossRef]
2. Padilla-Galo A, Olveira C, Fernández de Rota-García L, Marco-Calvi J, Plata AJ, Alvaraz A, et al. Factors associated with bronchiectasis in patients with uncontrolled asthma; the NOPES score: a study in 398 patients. Respir Res 2018;19:43. [CrossRef]
3. Zhang SQ, Xiong XF, Wu ZH, Huang TT, Cheng DY. Clinical features of asthma with comorbid bronchiectasis: A systematic review and meta-analysis. Medicine (Baltimore) 2021;100:e23858.
4. Crimi C, Ferri S, Campisi R, Crimi N. The link between asthma and bronchiectasis: state of the art. Respiratation 2020;99:463–76. [CrossRef]
5. Polverino E, Dimakou K, Hurst J, Martinez-Garcia MA, Miravitlles M, Paggiaro P, et al. The overlap between bronchiectasis and chronic airway diseases: state of the art and future directions. Eur Respir J 2018;52:1800328. [CrossRef]
6. Polverino E, Goeminne PC, McDonnell MJ, Aliberti S, Marshall SE, Loebinger MR, et al. European Respiratory Society guidelines for the management of adult bronchiectasis. Eur Respir J 2017;50:1700629. [CrossRef]
7. Maglione M, Aksamit T, Santamaria F. Paediatric and adult bronchiectasis: Specific management with coexisting asthma, COPD, rheumatological disease and inflammatory bowel disease. Respirology 2019;24:1063–72. [CrossRef]
8. Lonni S, Chalmers JD, Goeminne PC, McDonnell MJ, Dimakou K, De Soyza A, et al. Etiology of non-cystic fibrosis bronchiectasis in adults and its correlation to disease severity. Ann Am Thorac Soc 2015;12:1764–70. [CrossRef]
9. Ferri S, Crimi C, Campisi R, Cacopardo G, Paoletti G, Puggioni F, et al. Impact of asthma on bronchiectasis severity and risk of exacerbations. J Asthma 2020:1–12. [CrossRef]
10. Mäntylä J, Mazur W, Törölä T, Bergman P, Saarinen T, Kauppi P. Asthma as aetiology of bronchiectasis in Finland. Respir Med 2019;152:105–11. [CrossRef]
11. Wang D, Luo J, Du W, Zhang LL, He LX, Liu CT. A morphologic study of the airway structure abnormalities in patients with asthma by high-resolution computed tomography. J Thorac Dis 2016;8:2697–708. [CrossRef]
12. Amati F, Franceschi E, Gramegna A, Chalmers JD, Aliberti S. Investigating the etiology of bronchiectasis: you do not find what you do not look for. Respiratation 2017;93:228–9. [CrossRef]
13. Sears MR. Trends in the prevalence of asthma. Chest 2014;145:219–25. [CrossRef]
14. Fildan AP, Toma CL, Toftelean D, Balteanu M, Dantes E. Overlapping tuberculosis in a patient with pulmonary alveolar proteinosis. Acta Medica Mediterr 2016;32:1021–5.
15. Crisan-Dabija RA, Mihaescu T. Interstitial lung diseases misdiag-
nosis: a Healthcare Improvement Science (HIS) approach. Eur Respir J 2018;52:PA2983. [CrossRef]

16. Dimakou K, Gousiou A, Toumbis M, Kaponi M, Chrysikos S, Thanos L, et al. Investigation of bronchiectasis in severe uncontrolled asthma. Clin Respir J 2018;12:1212–8. [CrossRef]

17. Coman I, Pola-Bibian B, Barranco P, Vila-Nadal G, Dominguez-Ortega J, Romero D, et al. Bronchiectasis in severe asthma: Clinical features and outcomes. Ann Allergy Asthma Immunol 2018;120:409–13. [CrossRef]

18. Pagani F, Séneterre E, Chanez P, Daurès JP, Bruel JM, Michel FB, et al. Computed tomography of the lungs in asthma: influence of disease severity and etiology. Am J Respir Crit Care Med 1996;153:110–4. [CrossRef]

19. Pang J, Chan HS, Sung JY. Prevalence of asthma, atopy, and bronchial hyperreactivity in bronchiectasis: a controlled study. Thorax 1989;44:948–51. [CrossRef]

20. Ogunzulgen IK, Kervan F, Ozis T, Turktas H. The impact of bronchiectasis in clinical presentation of asthma. South Med J 2007;100:468–71. [CrossRef]

21. Mao B, Yang JW, Lu HW, Xu JF. Asthma and bronchiectasis exacerbation. Eur Respir J 2016;47:1680–6. [CrossRef]

22. Dunnill M. The pathology of asthma, with special reference to changes in the bronchial mucosa. J Clin Pathol 1960;13:27–33.

23. Ledrup Carlson KC, Hedlin G, Bush A, Wennergren G, de Benedictis FM, De Jongste JC, et al; P-SACI (Problematic Severe Asthma in Childhood Initiative) group. Assessment of problematic severe asthma in children. Eur Respir J 2011;37:432–40. [CrossRef]

24. Bisaccioni C, Aun MV, Cajuela E, Kalil J, Agondi RC, Giavina-Bianchi P. Comorbidities in severe asthma: frequency of rhinitis, nasal polyposis, gastroesophageal reflux disease, vocal cord dysfunction and bronchiectasis. Clinics (Sao Paulo) 2009;64:769–73. [CrossRef]

25. Loftus BG, Price JF, Lobo-Yeo A, Vergani D. IgG subclass deficiency in asthma. Arch Dis Child 1988;63:1434–7. [CrossRef]

26. de Moraes Lui C, Oliveira LC, Diogo CL, Kirschfink M, Grumach DI, et al. Cystic fibrosis: scoring system with thin-section CT. Radiol Bras 2018;51:406–11. [CrossRef]

27. Luján M, Gallardo X, Amengual MJ, Bosque M, Mirapeix RM, Nicolau J, et al. Severe uncontrolled asthma: CSF evaluation of disease severity and etiology. Allergy 2011;66:679–85. [CrossRef]

28. Bhatia C, Haines K, Jokhoo A, Panesar H, Cianfrone G. Asthma and bronchiectasis. J Allergy Clin Immunol 2021;147:1088–94. [CrossRef]

29. Oţelea M, Raşcu A, Elena Popa D, Otelea M. Effects of corticosteroid treatment on respiratory muscles function in patients with severe obstructive lung disease. Farmacia 2016;64:819–22.

30. Otelea M, Raşcu A, Postolache P. Interrelationship between pathophysiological mechanisms of vitamin D deficit and chronic obstructive pulmonary disease. Rev Med Chir Soc Med Nat Iasi 2016;120:497–502.

31. Huang YJ. The respiratory microbiome and innate immunity in asthma. Curr Opin Pulm Med 2015;21:27–32. [CrossRef]

32. Huang YJ, Boushey HA. The microbiome in asthma. J Allergy Clin Immunol 2015;135:25–30. [CrossRef]

33. Rascu A, Elena Popa D, Arghir O, Otelea M. Effects of corticosteroid treatment on respiratory muscles function in patients with severe obstructive lung disease. Farmacia 2016;64:819–22.

34. Rascu A, Elena Popa D, Arghir O, Otelea M. Effects of corticosteroid treatment on respiratory muscles function in patients with severe obstructive lung disease. Farmacia 2016;64:819–22.

35. Oţelea M, Raşcu A, Postolache P. Interrelationship between pathophysiological mechanisms of vitamin D deficit and chronic obstructive pulmonary disease. Rev Med Chir Soc Med Nat Iasi 2016;120:497–502.

36. Huang YJ. The respiratory microbiome and innate immunity in asthma. Curr Opin Pulm Med 2015;21:27–32. [CrossRef]

37. Huang YJ, Boushey HA. The microbiome in asthma. J Allergy Clin Immunol 2015;135:25–30. [CrossRef]

38. Chang HS, Lee TH, Jun JA, Baek AR, Park JS, Koo SM, et al. Neutrophilic inflammation in asthma: mechanisms and therapeutic considerations. Expert Rev Respir Med 2017;11:29–40. [CrossRef]

39. Whitters D, Stockley R. Immunity and bacterial colonisation in bronchiectasis. Thorax 2012;67:1006–13. [CrossRef]

40. Chalmers JD, Goeminne P, Aliberti S, McDonnell MJ, Lonni S, Davidson J, et al. The bronchiectasis severity index. An international derivation and validation study. Am J Respir Crit Care Med 2014;189:576–85. [CrossRef]

41. Porsbjerg C, Menzies-Gow A. Co-morbidities in severe asthma: a pilot study of an emerging phenotype that responds to mepolizumab. J Asthma Allergy 2019;12:83–90. [CrossRef]

42. Porsbjerg C, Menzies-Gow A. Co-morbidities in severe asthma: a pilot study of an emerging phenotype that responds to mepolizumab. J Asthma Allergy 2019;12:83–90. [CrossRef]

43. Oţelea M, Raşcu A, Elena Popa D, Otelea M. Effects of corticosteroid treatment on respiratory muscles function in patients with severe obstructive lung disease. Farmacia 2016;64:819–22.

44. Porsbjerg C, Menzies-Gow A. Co-morbidities in severe asthma: a pilot study of an emerging phenotype that responds to mepolizumab. J Asthma Allergy 2019;12:83–90. [CrossRef]

45. Porsbjerg C, Menzies-Gow A. Co-morbidities in severe asthma: a pilot study of an emerging phenotype that responds to mepolizumab. J Asthma Allergy 2019;12:83–90. [CrossRef]

46. Garcia-Clemente M, Enríquez-Rodríguez AI, Iscar-Urrutia M, Escribano MP. Severe uncontrolled asthma with bronchiectasis: a pilot study of an emerging phenotype that responds to mepolizumab. J Asthma Allergy 2019;12:83–90. [CrossRef]

47. Garcia-Clemente M, Enríquez-Rodríguez AI, Iscar-Urrutia M, Escribano MP. Severe uncontrolled asthma with bronchiectasis: a pilot study of an emerging phenotype that responds to mepolizumab. J Asthma Allergy 2019;12:83–90. [CrossRef]

48. Oţelea M, Raşcu A, Elena Popa D, Otelea M. Effects of corticosteroid treatment on respiratory muscles function in patients with severe obstructive lung disease. Farmacia 2016;64:819–22.

49. Oţelea M, Raşcu A, Elena Popa D, Otelea M. Effects of corticosteroid treatment on respiratory muscles function in patients with severe obstructive lung disease. Farmacia 2016;64:819–22.

50. Oţelea M, Raşcu A, Elena Popa D, Otelea M. Effects of corticosteroid treatment on respiratory muscles function in patients with severe obstructive lung disease. Farmacia 2016;64:819–22.

51. Zaharie AM, Antoniu S, Wynimko JC, Mihaltan FD, Deleanu OC,
Mahler B, et al. Romanian pilot study of alpha-1 antitrypsin detection-feasibility and challenges. Rev Chim 2018;69:1152–5. [CrossRef]

52. Chanez P, Israel E, Davidescu L, Ursol G, Korzh O, Deshmukh V, et al. Masitinib significantly decreases the rate of asthma exacerbations in patients with severe asthma uncontrolled by oral corticosteroids: a phase 3 multicenter study. Am J Respir Crit Care Med 2020;201:A4210. [CrossRef]

53. Henkle E, Curtis JR, Chen L, Chan B, Aksamit TR, Daley CL, et al. Comparative risks of chronic inhaled corticosteroids and macrolides for bronchiectasis. Eur Respir J 2019;54:1801896. [CrossRef]

54. Rademacher J, Konwert S, Fuge J, Dettmer S, Welte T, Ringshausen FC. Anti-IL5 and anti-IL5Rα therapy for clinically significant bronchiectasis with eosinophilic endotype: a case series. Eur Respir J 2020;55:1901333. [CrossRef]

55. Brusselle GG, Joos G. Is there a role for macrolides in severe asthma? Curr Opin Pulm Med 2014;20:95–102. [CrossRef]